🇺🇸 FDA
Patent

US 8575165

Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds

granted A61KA61K31/506A61P

Quick answer

US patent 8575165 (Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds) held by Rigel Pharmaceuticals, Inc. expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K31/506, A61P, A61P1/04, A61P11/00